A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Public ClinicalTrials.gov record NCT05785624. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Two-Cohort, Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Vixarelimab Compared With Placebo in Patients With Idiopathic Pulmonary Fibrosis and in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks. Cohort 1 has completed enrollment and has been closed for further enrollment. Cohort 2 is enrolling participants.
Study identification
- NCT ID
- NCT05785624
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 286 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 25, 2023
- Primary completion
- Jan 11, 2026
- Completion
- Jan 11, 2026
- Last update posted
- Feb 8, 2026
2023 – 2026
United States locations
- U.S. sites
- 28
- U.S. states
- 14
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| Banner University Medicine Lung Institute | Phoenix | Arizona | 85006-2506 | — |
| Southern Arizona VA Health Care System NAVREF PPDS | Tucson | Arizona | 85723-0001 | — |
| University of California, San Francisco-Fresno | Fresno | California | 93701-2302 | — |
| University of Southern California Keck School of Medicine | Los Angeles | California | 90033-1036 | — |
| UCLA Rheumatology | Los Angeles | California | 90095-8344 | — |
| University of California, San Francisco Medical Center | San Francisco | California | 94143-2204 | — |
| The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente | Torrance | California | 90502 | — |
| Renstar Medical Research | Ocala | Florida | 34470 | — |
| Coastal Pulmonary and Critical Care PLC | St. Petersburg | Florida | 33704-2733 | — |
| Weston Hospital | Weston | Florida | 33331-3609 | — |
| Piedmont Pulmonary and Sleep Medicine Buckhead | Atlanta | Georgia | 30309-1740 | — |
| Emory Clinic | Atlanta | Georgia | 30322 | — |
| GenHarp Clinical Solutions | Evergreen Park | Illinois | 60805-2758 | — |
| Northwestern Medicine - Northwestern Medicine Glen | Glenview | Illinois | 60026-8039 | — |
| IU Health Ball Memorial Physicians Pulmonary and Critical Care Medicine | Muncie | Indiana | 47303-3432 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| University of Michigan Hospital | Ann Arbor | Michigan | 48109 | — |
| Hannibal Regional Healthcare System HRMG Hannibal | Hannibal | Missouri | 63401-6890 | — |
| Pulmonix LLC | Greensboro | North Carolina | 27403-4443 | — |
| Southeastern Research Center | Winston-Salem | North Carolina | 27103-4029 | — |
| The University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104-5417 | — |
| Baylor Scott and White Health - Advanced Lung Disease Specialists - Dallas | Dallas | Texas | 75246-2073 | — |
| IntraCare Health Center ? Prestige | Dallas | Texas | 75254 | — |
| El Paso Pulmonary Association Elligo PPDS | El Paso | Texas | 79902-1124 | — |
| McGovern Medical School | Houston | Texas | 77030-1501 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| University of Utah - PPDS | Salt Lake City | Utah | 84108-1287 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.
Recently updated Idiopathic Pulmonary Fibrosis trials
Other public records listing Idiopathic Pulmonary Fibrosis. Sorted by last update posted; newest first. Not a recommendation.
- NCT06325696: H01 in Adults With Interstitial Lung Disease (The SOLIS Study) Recruiting
- NCT05389215: Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF Active, not recruiting
- NCT07671911: Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets Recruiting
- NCT07674745: Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis Not yet recruiting
- NCT05241275: Xenon MRI and Progressive ILD Active, not recruiting
- NCT00470327: A Study of the Natural Progression of Interstitial Lung Disease (ILD) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05785624, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 8, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05785624 live on ClinicalTrials.gov.